Research and Development (RD)

Network Bio partners with Duke University on AI disease models

US-based Network Bio has entered into a research collaboration with Duke University to develop artificial intelligence (AI) models of human disease using biospecimens and clinical records.

Evommune signs $1.1bn licence deal with Hinova for EVO570

Evommune has secured exclusive rights outside Greater China to develop, manufacture and commercialise EVO570, an autoimmune therapy, from Hinova Pharmaceuticals in a licence deal worth up to around $1.1bn.

Hovione finalises $100m investment for East Windsor site expansion in US

Hovione has concluded an initial $100m investment cycle for expanding its manufacturing site in East Windsor, New Jersey, as part of its strategy to extend operations in the US and broaden drug substance and product capabilities.

Radar Therapeutics secures $13.4m to develop programmable medicines

Radar Therapeutics has successfully completed an oversubscribed seed funding round, raising $13.4m for developing smart programmable medicines.

Gilead Sciences selects AWS as preferred cloud provider

US-based biopharmaceutical company Gilead Sciences has selected Amazon Web Services (AWS) as its preferred cloud provider.

Revive Therapeutics, UCSF partner to study Bucillamine for severe Covid-19

Specialty life sciences company Revive Therapeutics has signed a research agreement with University of California, San Francisco (UCSF) to study Bucillamine as a potential treatment for severe Covid-19.

Dyadic and Medytox to co-develop Covid-19 variant fighting vaccines

US-based global biotechnology company Dyadic International has announced the expansion of its partnership with South Korea-based global research biopharmaceutical company Medytox to co-develop C1 manufactured Covid-19 vaccines.

USFDA grants priority review to Merck’s NDA for HIF-2α inhibitor Belzutifan

The US Food and Drug Administration (FDA) has granted priority review for Merck’s New Drug Application (NDA) for the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan.

NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.